Introduction

HIV-1 Infection of the Nervous System Comes of Age
By Karl Goodkin, MD, PhD, FAPA Early in the acquired immunodeficiency syndrome (AIDS) epidemic, human immunodeficiency virus type 1 (HIV-1) infection of the nervous system was largely confined to the central nervous system (CNS). Originally, the concept of a dementia due to HIV-1 was challengedthought to be better attributed to a complicating infection, such as cytomegalovirus encephalopathy. However, studies investigating pathology in the brains of infants and children infected with HIV-1 provided evidence that the dementia is actually caused by HIV-1 itself.
In the lead article of this issue, Paul Shapshak, PhD, and colleagues thoroughly examine the importance of the load of HIV-1 in the brain. Unlike research focusing on the periphery, research on the CNS has been predominantly focused on indirect mechanisms of cell death and inflammatory mediators. Shapshak et al discuss the possibility that independent clustering and evolution of virus occurs normally across brain regions over time, as well as the importance of strain variation related to neurovirulence. In addition, the attention given to the molecular epidemiology of the virus incorporates a novel aspect of work.Cytokines and chemokines, which have been the predominant mechanistic focus of research, are also thoroughly considered.
From the early stages of the epidemic, the issue that the dementia was a diagnosis of exclusion was highly clinically relevant (Mauricio Concha, MD, MHS, and Alejandro Rabinstein, MD). Toxoplasmosis frequently caused lesions in the brain and CNS lymphoma was already the second most common mass lesion in these patients. Cryptococcal meningitis was also a frequent cause of morbidity and mortality. In addition, less common fungal infections in the CNS are discussed-histoplasmosis, coccidioidomycosis, mucormycosis, blastomycosis, Candida, and aspergillosis. Over time, it became clear that neurosyphilis was frequently overlooked, could be asymptomatic, and may appear despite a negative serological test for syphilis-heralding the return of syphilis as the "great masquerader." In addition, tuberculosis increased in incidence and made a continued climb as the AIDS epidemic grew. As a result, tuberculous meningitis became an important entity to screen as well. Other less common bacterial infections of the CNS are also discussed-Mycobacterium avium complex (which is much more common in the periphery), listeriosis, and nocardiosis. Progressive multifocal leukoencephalopathy stood out as an opportunistic viral infection that struck fear into patients and seemed hopeless to treat. In addition, other viral encephalopathies are discussedcytomegalovirus, herpes simplex virus, and varicella zoster virus. With this plethora of conditions to screen, it became incumbent upon neuropsychiatrists as well as neurologists to familiarize themselves with these conditions. Nutrition has been studied as a cofactor of HIV-1 clinical disease progression systemically, as well as specifically in neuroAIDS conditions. Since the beginning of the epidemic, the patients have been interested in nutritional intervention for longevity and treatment of symptoms and illnesses associated with HIV-1 infection. Teri Baldewicz, PhD, and colleagues present an excellent review of the data regarding how nutritional deficiencies may contribute to the cognitive dysfunction, neurologic abnormalities, mood disturbances, and immune dysregulation associated with HIV-1 infection. Of relevance to peripheral neuropathy to be covered in the next issue, pyridoxine and cobalamin are addressed, along with their effects on other outcomes, such as mood. S-adenosyl methionine and folate are discussed in conjunction with cobalamin in terms of 1-carbon fragment metabolism. Oxidative stress is a pathophysiological mechanism of major interest for several illnesses in the field of neuroAIDS (relevant to deficiencies in vitamins A and E, as well as selenium). In addition, zinc has a clinically relevant role as an immunostimulant as well as other roles in neuroAIDS conditions. The recent interest in polyunsaturated fatty acids and lipids in HIV-1 infection is approached from the perspective of neuroAIDS therein as well. Finally, this article ends with a consideration of nutritional issues in special populations-children and substance users. Overall, this article is one of the most comprehensive, up-to-date presentations available on nutritional relationships in neuroAIDS conditions. In summary, this first issue of two issues on neuroAIDS is focused on the virological mechanisms of HIV-1-associated dementia, on a review of complications of HIV-1 in the CNS, and on a comprehensive and current review of nutritional relationships with a mechanistic focus. These foci make this issue important reading for any neurologist or neuropsychiatrist seeing HIV-1 infected patients.
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CarfcTatroF carbamazepine extended-release capsules 200 mg capsule ~ 300 mg capsule Before prescribing Carbatrol, the physician should be thoroughly familiar with the details of the full prescribing Information, particularly regarding use with other drugs, especially those which accentuate toxlclty potential.
INDICATIONS AND USAGE Epilepsy
Carbatrol* is Indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: 1. Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvements than those with other types. 2. Generalized tonic-clonic seizures (grand mal). 3. Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General).
Trlgeminal Neuralgia
Carbatrol is indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. CONTRAINDICATIONS Carbamazepine should not be used in patients with a history of previous bone marrow depression, hypersensitivity to the drug, or known sensitivity to any of the tricyciic compounds, such as amitriptyline, desipramine, irnipramine, protriptyline and nortriptyline. Likewise, on theoretical grounds its use with monoamine oxidase inhibitors is not recommended. Before administration of carbamazepine, MAO inhibitors should be discontinued for a minimum of 14 days, or longer if the clinical situation permits.
WARNINGS Usage in Pregnancy
Carbamazepine can cause fetal harm when administered to a pregnant woman. Epidemiological data suggest that there may be an association between the use of carbamazepine during pregnancy and congenital malformations, including spina bifida. The prescribing physician will wish to weigh the benefits of therapy against the risks in treating or counseling women of childbearing potential. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Retrospective case reviews suggest that, compared with monotherapy, there may be a higher prevalence of teratogenic effects associated with the use of anticonvulsants in combination therapy. In humans, transplacental passage of carbamazepine is rapid (30-60 minutes), and the drug is accumulated in the fetal tissues, with higher levels found in liver and kidney than in brain and lung. Carbamazepine has been shown to have adverse effects in reproduction studies in rats when given orally in dosages 10-25 times the maximum human daily dosage (MHDD) of 1200 mg on a mg/kg basis or 1.5-4 times the MHDD on a mg/m ! basis. In rat teratology studies, 2 of 135 offspring showed kinked ribs at 250 mg/kg and 4 of 119 offspring at 650 mg/kg showed other anomalies (cleft palate, 1; talipes, 1; anophthalmos, 2). In reproduction studies in rats, nursing offspring demonstrated a lack of weight gain and an unkempt appearance at a maternal dosage level of 200 mg/kg. Antiepileptic drugs should not be discontinued abruptly in patients in whom the drug is administered to prevent major seizures because of the strong possibility of precipitating status epilepticus with attendant hypoxia and threat to life. In individual cases where the severity and frequency of the seizure disorder are such that removal of medication does not pose a serious threat to the patient, discontinuation of the drug may be considered prior to and during pregnancy, although it cannot be said with any confidence that even minor seizures do not pose some hazard to the developing embryo or fetus. Tests to detect defects using current accepted procedures should be considered a part of routine prenatal care in childbearing women receiving carbamazepine.
General
Patients with a history of adverse hematologic reaction to any drug may be particularly at risk. Severe dermatologic reactions, including toxic epidermal necrolysls (Lyell's syndrome) and Stevens-Johnson syndrome have been reported with carbamazepine. These reactions have been extremely rare. However, a few fatalities have been reported. Carbamazepine has shown mild anticholinergic activity; therefore, patients with increased intraocular pressure should be closely observed during therapy. Because of the relationship of the drug to other tricyciic compounds, the possibility of activation of a latent psychosis and, in elderly patients, of confusion or agitation should be considered. PRECAUTIONS General Before initiating therapy, a detailed history and physical examination should be made. Carbamazepine should be used with caution in patients with a mixed seizure disorder that includes atypical absence seizures, since in these patients carbamazepine has been associated with increased frequency of generalized convulsions (see INDICATIONS AND USAGEJ.Therapy should be prescribed only after critical benefitto-risk appraisal in patients with a history of cardiac, hepatic, or renal damage; adverse hematologic reaction to other drugs; or interrupted courses of therapy with carbamazepine.
Information for Patients
Patients should be made aware of the early toxic signs and symptoms of a potential hematologic problem, such as fever, sore throat, rash, ulcers in the mouth, easy bruising, petechial or purpuric hemorrhage, and should be advised to report to the physician immediately if any such signs or symptoms appear. Since dizziness and drowsiness may occur, patients should be cautioned about the hazards of operating machinery or automobiles or engaging in other potentially dangerous tasks. If necessary, the Carbatrol capsules can be opened and the contents sprinkled over food, such as a teaspoon of applesauce or other similar food products. Carbatrol capsules or their contents should not be crushed or chewed.
Laboratory Tests
Complete pretreatment blood counts, including platelets and possibly reticulocytes and serum iron, should be obtained as a baseline. If a patient in the course of treatment exhibits low or decreased white blood cell or platelet counts, the patient should be monitored closely. Discontinuation of the drug should be considered if any evidence of significant bone marrow depression develops. Baseline and periodic evaluations of liver function, particularly in patients with a history of liver disease, must be performed during treatment with this drug since liver damage may occur. The drug should be discontinued immediately in cases of aggravated liver dysfunction or active liver disease. Baseline and periodic eye examinations, including slit-lamp, funduscopy, and tonometry, are recommended since many phenothiazines and related drugs have been shown to cause eye changes. Baseline and periodic complete urinalysis and BUN determinations are recommended for patients treated with this agent because of observed renal dysfunction. Monitoring of blood levels (see CLINICAL PHARMACOLOGY) has increased the efficacy and safety of anticonvulsants. This monitoring may be particularly useful in cases of dramatic increase in seizure frequency and for verification of compliance. In addition, measurement of drug serum levels may aid in determining the cause of toxicity when more than one medication is being used. Thyroid function tests have been reported to show decreased values with carbamazepine administered alone. Hyponatremia has been reported in association with carbamazepine use, either alone or in combination with other drugs. Interference with some pregnancy tests has been reported. "Registered trademark of Shire Richwood Inc.
